

**Principal Investigator Notification:**

From: Mayo Clinic IRB

To: [Vitaly Herasevich](#)

CC: [Adil Ahmed](#)

[Andrew Hanson](#)

[Vitaly Herasevich](#)

[Tami Krpata](#)

[Man Li](#)

Re: **IRB Application #:** [13-002483](#)

Title: The use of research data mart quality improvement reports and clinical automatic calculators in ICU: one steps closer toward meaningful use

IRBe Protocol Version: 0.03

IRBe Version Date: 4/26/2013 9:31 AM

IRB Approval Date: 4/29/2013

IRB Expiration Date: 4/28/2014

The above referenced application is approved by expedited review procedures (45 CFR 46.110, item 5). The Reviewer conducted a risk-benefit analysis, and determined the study constitutes minimal risk research. The Reviewer determined that this research satisfies the requirements of 45 CFR 46.111.

The Reviewer approved waiver of the requirement to obtain informed consent in accordance with 45 CFR 46.116 as justified by the Investigator, and waiver of HIPAA authorization in accordance with applicable HIPAA regulations.

AS THE PRINCIPAL INVESTIGATOR OF THIS PROJECT, YOU ARE RESPONSIBLE FOR THE FOLLOWING RELATING TO THIS STUDY.

- 1) When applicable, use only IRB approved materials which are located under the documents tab of the IRBe workspace. Materials include consent forms, HIPAA, questionnaires, contact letters, advertisements, etc.
- 2) Submission to the IRB of any modifications to approved research along with any supporting documents for review and approval prior to initiation of the changes.
- 3) Submission to the IRB of all Unanticipated Problems Involving Risks to Subjects or Others (UPIRTSO).
- 4) Compliance with Mayo Clinic Institutional Policies.

Mayo Clinic Institutional Reviewer